| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5520983 | Drug Discovery Today | 2017 | 6 Pages |
â¢A comprehensive review of rHDL in treating cardiovascular diseases.â¢Presenting most of the laboratory experiments and clinical trials.â¢Providing guidance for future rHDL development.
The unique anti-atherosclerosis abilities and other cardioprotective properties make high-density lipoprotein (HDL) a promising solution in treating cardiovascular diseases. A number of studies showed that HDL-based therapy was well tolerated and has great potential in the future. Among all these new agents, the most studied ones including recombinant HDL, recombinant human apolipoproteins, apolipoprotein mimetic peptides and recombinant HDL used as contrast agents in cardiovascular imaging are discussed here. Recombinant HDL and apolipoproteins are promising in diagnosing and treating cardiovascular diseases.
